Continuous glucose monitors (CGMs) have become one of the most important tools in diabetes management — giving people real-time data on their blood sugar without constant fingersticks. But with device costs that can run into hundreds of dollars per month, insurance coverage isn't a minor detail. It's often the deciding factor in whether someone can actually use one.
Here's what you need to know about how coverage works, which factors determine eligibility, and what to look into before assuming you're covered — or that you're not.
A CGM is a wearable medical device that tracks glucose levels continuously throughout the day and night. A small sensor inserted under the skin reads glucose from interstitial fluid and transmits readings to a receiver, smartphone, or insulin pump — typically every few minutes.
The major CGM systems currently on the market include devices from manufacturers like Dexcom, Abbott (Freestyle Libre), Medtronic, and newer entrants targeting broader consumer audiences. Each system has different sensor wear times, accuracy profiles, and integration capabilities with other diabetes devices.
CGMs are broadly grouped into two categories:
This distinction matters enormously when it comes to coverage.
Coverage varies significantly by insurer, plan type, and how your plan categorizes the device. The two most common coverage pathways are:
Many insurers — including Medicare — cover prescription CGMs under the DME benefit. Under this pathway, the device and supplies (sensors, transmitters) are treated similarly to other medical equipment. Coverage typically requires:
Failure to use an approved DME supplier is a common reason claims are denied, even when the device itself would be covered.
Some plans — and some specific CGM products — are covered under the pharmacy benefit rather than DME. In these cases, you'd get the device filled at a pharmacy, and your pharmacy copay structure applies instead. This can sometimes mean lower out-of-pocket costs, but it depends entirely on how your specific plan is structured.
Some people have both options available and can choose the lower-cost pathway. Others only have one.
Coverage isn't a simple yes or no — it's shaped by a combination of factors:
| Factor | Why It Matters |
|---|---|
| Diagnosis type | Coverage criteria for Type 1 vs. Type 2 vs. gestational diabetes differ across plans |
| Insulin use | Some plans limit coverage to people using insulin; others have broader criteria |
| Plan type | Medicare, Medicaid, employer-sponsored, ACA marketplace, and private plans all operate differently |
| State regulations | Some states mandate CGM coverage under certain plans; others don't |
| Formulary placement | If covered under pharmacy benefit, what tier the device sits on affects your cost |
| Prior authorization | Many plans require advance approval and clinical documentation |
| In-network suppliers | Using out-of-network suppliers can result in denied claims or higher costs |
There's no universal rule. A plan that covers a Dexcom G7 may not cover a Freestyle Libre 3 — or may cover one under pharmacy benefits and another under DME.
Medicare has its own CGM coverage framework, and it's worth understanding separately. Medicare Part B covers CGMs classified as "therapeutic" — meaning they're used to make treatment decisions (like adjusting insulin doses) rather than just monitoring. Coverage under Part B generally requires:
Medicare also covers CGMs through Part D (prescription drug benefit) for some devices, and Medicare Advantage plans may have different rules. The interplay between Part B and Part D can affect your cost-sharing, so confirming which part applies to your specific device matters.
Medicaid CGM coverage varies by state, as states have significant discretion in setting their own coverage policies. Some states have expanded coverage broadly; others have more restrictive criteria. If you're on Medicaid, checking your state's specific formulary and medical policy is essential — what's true in one state may not apply in another.
A newer category of CGMs — including some Freestyle Libre models marketed directly to consumers — can be purchased without a prescription. These devices have made glucose monitoring more accessible in one sense, but they typically fall outside insurance coverage because they don't go through the prescription and DME or pharmacy benefit pathway.
This is an evolving area. Coverage policies may shift as these devices become more common and as clinical use cases are better established. But for now, if a CGM is purchased OTC, don't assume insurance will reimburse it without verifying your specific plan's policy.
Even when a CGM is covered in principle, prior authorization (PA) is often required. This means your prescriber must submit clinical documentation to your insurer before coverage is approved. Common documentation requests include:
PA is sometimes denied on the first submission — and successfully appealed with additional documentation. If you receive a denial, understanding whether to appeal (and what documentation supports an appeal) is worth exploring with your prescriber and insurer.
If you're trying to understand your own coverage situation, here's the landscape you'd need to evaluate:
The right answer for any individual depends on the intersection of their medical profile, their specific insurance plan, and the device they're considering. Understanding the landscape is the first step — but verifying the details with your insurer and prescriber is where the real work happens.
